Adjuvant radiotherapy in malignant tumors of parotid. Experience of the Navarra Hospital Complex.

Autor:	Mendizábal MR; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., Andueza SF; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., Sarda IQ; Maxillofacial Surgery Services, Navarra Hospital Complex, Pamplona, Spain., Campo M; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., Felipe GA; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., Gutierrez LR; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., Gomez AB; Radiation Oncology, Navarra Hospital Complex, Pamplona, Spain., de la Vega FA; Maxillofacial Surgery Services, Navarra Hospital Complex, Pamplona, Spain.
Jazyk:	angličtina
Zdroj:	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2021 Dec 30; Vol. 26 (6), pp. 962-967. Date of Electronic Publication: 2021 Dec 30 (Print Publication: 2021).
DOI:	10.5603/RPOR.a2021.0118
Abstrakt:	Background: The objective of the study was to review the outcome of patients with parotid cancer treated with postoperative radiotherapy at Complejo Hospitalario de Navarra in the last ten years. Materials and Methods: We retrospectively reviewed patients treated with adjuvant radiotherapy between January 2008 and December 2018. We analyzed demographic data, histopathologic findings, local control (LC) and overall survival (OS). Results: A total of 40 patients received postoperative radiotherapy during the period mentioned. There were 22 men (55%) and 18 women (45%). Median age was 58 years (19-90). By tumor histology, the most common was squamous cell carcinoma (22.5%) followed by ex-pleomorphic adenoma (15%) and adenoid cystic carcinoma (10%). According to Surgery, 19 patients (47.5%) underwent a total parotidectomy, 20 (50%) partial parotidectomy, and 1 (2.5%) a radical parotidectomy. Twenty-one patients (51.2%) underwent cervical dissection, most of them being supraomohyoid (31.7%). Reasons for adjuvant RT were: R1 resection (35% of the patients), high grade tumors (27.5%) and 17.5% because R1 surgery and R1. Radiation was administered using IMRT in most patients to a total dose of 60 Gy in 30 fractions. The 5-year overall survival (OS) (Kaplan-Meier) was 81% (95% CI: 68.5-96.2%), and 10-years - 64%. The 5-year local control (LC) (Kaplan-Meier) was 82.4% (95% CI: 91.46-73.33%) and the 10-year LC - 72.2% (95% CI: 54.9-96%). To date, only 4 patients (10%) have died due to their parotid tumor. Conclusion: The adjuvant radiotherapy added to surgery, significantly reduces the risk of recurrence in high-risk patients with a very acceptable survival rate. Competing Interests: Conflicts of interest None declared. (© 2021 Greater Poland Cancer Centre.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu